Upcoming Presentation Highlights at SITC Annual Meeting
Compass Therapeutics, Inc. (Nasdaq: CMPX), a pioneering biopharmaceutical firm devoted to oncology, is thrilled to announce the acceptance of a significant abstract which will be presented in poster format at the highly anticipated 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. This event is set to take place from November 8 to November 10 in a prominent convention center.
Insights on the Poster Presentation
Attendees can look forward to engaging with groundbreaking research encapsulated in the poster titled:
Pharmacodynamic and Response Biomarkers
The emphasis will be on the monotherapy arm of a Phase 1 trial focusing on CTX-471, a cutting-edge anti-CD137 agonist antibody. This presentation aims to shed light on crucial pharmacodynamic metrics and response biomarkers that could significantly influence future therapeutic approaches.
Collaboration of Notable Authors
The research is authored by a team of esteemed professionals including Kris Sachsenmeier, Niharika Mettu, and more, showcasing a diverse mix of expertise aimed at pushing the boundaries of cancer treatment.
Key Presentation Details for Attendees
Those interested in this innovative presentation can visit Exhibit Halls AB during the specified dates. The poster presentation will be available for review on Friday, November 8, from 9 AM to 7 PM CDT. Be sure to mark your calendars and prepare to delve into the data!
About Compass Therapeutics
Founded in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing novel antibody-based therapies. The company is committed to addressing various human diseases through innovative approaches.
Compass is not only focused on the development of therapeutics but also on understanding and exploiting the intricate relationship between angiogenesis, the immune response, and tumor growth. Their evolving pipeline features a variety of promising product candidates uniquely designed to tap into critical biological pathways essential for eliciting a robust anti-tumor response.
Driving Research and Development
The team at Compass is dedicated to advancing its portfolio through clinical stages, whether as standalone agents or in synergistic combination with other proprietary antibodies. The ultimate goal is to leverage both clinical and preclinical findings to maximize treatment efficacy.
Looking Toward the Future
As Compass Therapeutics prepares for this impactful presentation, the company continues to foster an environment of innovation and research excellence. The team invites the scientific community and interested parties to engage with their findings as they work towards enhanced treatment modalities for patients dealing with cancer.
Frequently Asked Questions
What is the primary focus of Compass Therapeutics?
Compass Therapeutics specializes in developing antibody-based therapies primarily targeting oncology and other diseases.
Where will the SITC Annual Meeting be held?
The 39th Society for Immunotherapy of Cancer Annual Meeting will take place at the George R. Brown Convention Center.
What is CTX-471?
CTX-471 is a novel anti-CD137 agonist antibody currently under investigation in clinical trials.
How can I find more information on Compass Therapeutics?
For further details, visit the official Compass Therapeutics website to explore their ongoing research and product developments.
Who are the key authors of the upcoming presentation?
The poster presentation will feature significant contributions from researchers such as Kris Sachsenmeier and Niharika Mettu, among others.
